Brokers Offer Predictions for Eyenovia, Inc.’s FY2025 Earnings (NASDAQ:EYEN)

Eyenovia, Inc. (NASDAQ:EYEN) – Analysts at William Blair issued their FY2025 earnings per share estimates for shares of Eyenovia in a research note issued on Tuesday, November 14th. William Blair analyst T. Lugo anticipates that the company will post earnings of ($0.86) per share for the year. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Eyenovia’s current full-year earnings is ($0.68) per share.

A number of other equities research analysts also recently weighed in on the stock. HC Wainwright restated a “buy” rating and issued a $12.00 price target on shares of Eyenovia in a research note on Tuesday. Brookline Capital Management initiated coverage on shares of Eyenovia in a research report on Tuesday, October 17th. They issued a “buy” rating and a $8.00 target price on the stock.

Eyenovia Stock Performance

Eyenovia stock opened at $1.25 on Wednesday. The company has a current ratio of 5.73, a quick ratio of 5.73 and a debt-to-equity ratio of 1.25. Eyenovia has a 12-month low of $1.05 and a 12-month high of $5.85. The business’s 50-day moving average price is $1.48 and its two-hundred day moving average price is $2.24.

Institutional Trading of Eyenovia

A number of hedge funds have recently made changes to their positions in EYEN. Virtu Financial LLC bought a new position in Eyenovia in the 4th quarter valued at approximately $26,000. Two Sigma Securities LLC acquired a new position in shares of Eyenovia during the second quarter worth $27,000. Goldman Sachs Group Inc. acquired a new position in shares of Eyenovia during the second quarter worth $28,000. American International Group Inc. bought a new stake in shares of Eyenovia in the second quarter worth $32,000. Finally, Prudential Financial Inc. acquired a new stake in Eyenovia in the second quarter valued at $33,000. 16.66% of the stock is owned by institutional investors and hedge funds.

About Eyenovia

Eyenovia, Inc, a pre-commercial ophthalmic company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. It focuses on developing clinical microdosing of formulations of ophthalmic pharmaceutical agents using its Optejet branded targeted ocular delivery system.